Unchained Labs Sold to The Carlyle Group

Unchained Labs Sold to The Carlyle Group

Private equity is branching out. Firms are usually swarming the physician group and behavioral health markets, building regional platforms, but we’re now seeing plenty of activity in new sectors, such as healthcare technology and research organizations. With fields such as diagnostics and gene therapy on the rise, it only makes sense for private equity to want a stake in the game. Last week, D.C.-based The Carlyle Group LP (NASDAQ: CG) announced it was buying Unchained Labs from Novo Holdings A/S, Canaan Partners, and TPG Biotech. The deal is valued at $435 million, or 5.80x Unchained Labs’ estimated 2021 revenue.  Unchained Labs is a life science tools company focused on solving problems... Read More »
SomaLogic Goes Public With SPAC

SomaLogic Goes Public With SPAC

They just don’t stop coming. Another private healthcare company has agreed to go public via SPAC in a $1.23 billion deal. SomaLogic is merging with CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company affiliated with Casdin Capital, LLC and Corvex Management LP. SomaLogic is a commercial-stage proteomics company with over 300 established industry partnerships and customers. The company’s pioneering technology platform, SomaScan Assay, measures 7,000 human proteins in a single sample, enabling the possibility of faster, more precise drug discovery for researchers. Artificial intelligence and machine learning-powered bioinformatics algorithms operating in tandem... Read More »
Roche Holding Acquires GenMark Diagnostics

Roche Holding Acquires GenMark Diagnostics

Last week, the pharmaceutical giant Roche Holding AG (SIX: RO) announced a new acquisition for GenMark Diagnostics (NASDAQ: GNMK), a Carlsbad, California lab services company. GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics and reduce the total cost-of-care. GenMark’s eSensor XT-8 and ePlex systems are designed to support a broad range of molecular diagnostic sample-to-answer tests with compact, easy-to-use workstations and self-contained, disposable test cartridges.  The deal is valued at $1.8 billion cash, or $24.05 per share, a premium of... Read More »
Quest Diagnostics Acquires Lab Division from Mercy

Quest Diagnostics Acquires Lab Division from Mercy

In an effort to expand its network, Quest Diagnostics (NYSE: DGX) has announced a deal with not-for-profit Mercy, a multi-state healthcare system. Quest is acquiring the health system’s outreach laboratory services business, which currently operates from 29 hospital laboratories and two independent clinic laboratories in Arkansas, Kansas, Missouri and Oklahoma.  No terms were disclosed in the all-cash transaction, but under the agreement, testing associated with outreach lab services will transition to the Quest Diagnostics full-service laboratory in Lenexa, Kansas, and a network of rapid response laboratories across the region. Mercy will continue to wholly own and operate its hospital... Read More »
Veracyte Snaps Up Decipher Biosciences, Inc.

Veracyte Snaps Up Decipher Biosciences, Inc.

Veracyte, Inc. (NASDAQ: VCYT), the South San Francisco, California-based diagnostics company, has bought Decipher Biosciences, Inc for $600 million consisting of $250 million in cash and up to $350 million in stock. Decipher Biosciences is a commercial-stage precision oncology company focused on urologic cancers. It has a comprehensive portfolio of tests which leverage whole transcriptome analysis and proprietary machine learning algorithms to improve patient decision-making across the clinical care continuum. This acquisition solidifies Veracyte’s global position in the genomic cancer diagnostics market while accelerating revenue growth. Collectively, Decipher’s genomic tests have... Read More »
Thermo Fisher Acquires Henogen S.A.

Thermo Fisher Acquires Henogen S.A.

After a surprise collapse of its takeover bid for QIAGEN N.V. (NYSE: QGEN), Thermo Fisher Scientific Inc. (NYSE: TMO) is back with a new deal in 2021. Thermo Fisher is buying Henogen S.A. from Groupe Novasep SAS for approximately EUR 725 million ($877.5 million) in cash. Based in Belgium, Henogen S.A. is a viral vector manufacturing business that provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers.  Groupe Novasep partners with a variety of industries to provide technically optimized and economical solutions for the life science industry.  Henogen has two facilities and approximately 400 employees with substantial... Read More »